$SAVA
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Healthcare
Sector
Biotechnology
Industry
Richard Jon Barry
CEO
30
Employees
$1.96
Current Price
$100.96M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
No transactions in the last 3 months. Sign up free to see 12 months of history.
Upcoming Earnings
Scheduled earnings reports
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated-$0.30
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated-$0.30
Actual-$0.26
Beat
Revenue
EstimatedN/A
ActualN/A
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals